The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 02, 2016
Filed:
Mar. 25, 2014
Applicant:
Pfizer Vaccines Llc, New York, NY (US);
Inventors:
Brian Robert Champion, Kent, GB;
David Robert Stead, Del Mar, CA (US);
Paul Andrew Wright, San Diego, CA (US);
Assignee:
Pfizer Vaccines LLC, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 17/06 (2006.01); A61K 39/00 (2006.01); C07K 16/42 (2006.01); A61K 39/44 (2006.01); A61K 47/48 (2006.01); A61K 38/10 (2006.01); A61K 39/385 (2006.01); C07K 4/12 (2006.01); C07K 7/08 (2006.01);
U.S. Cl.
CPC ...
C07K 17/06 (2013.01); A61K 39/0005 (2013.01); A61K 39/44 (2013.01); A61K 47/48023 (2013.01); C07K 16/4291 (2013.01); A61K 38/10 (2013.01); A61K 39/385 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6075 (2013.01); A61K 2039/6081 (2013.01); A61K 2039/70 (2013.01); A61K 2300/00 (2013.01); C07K 4/12 (2013.01); C07K 7/08 (2013.01); C07K 2316/52 (2013.01); C07K 2317/52 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2319/55 (2013.01); Y10S 424/805 (2013.01); Y10S 424/81 (2013.01); Y10S 530/806 (2013.01); Y10S 530/862 (2013.01); Y10S 530/866 (2013.01); Y10S 530/868 (2013.01);
Abstract
The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.